CSF1R and neoplasm: By combining paclitaxel with a CSF1R signaling antagonist, studies have shown an effective reduction in macrophage recruitment to tumor sites, thereby enhancing the drug’s effectiveness and reducing tumor progression and metastasis in preclinical models (Mantovani et al., 2022).